A double-blind placebo controlled trial of simvastatin for the treatment of dyslipidaemia in renal allograft recipients

Clinical Transplantation

Volumn 13, Issue 6, 1999, Pages 520-525

  Lepre, Frank ^a   Rigby, Russell ^a   Hawley, Carmel ^a   Saltissi, David ^b   Brown, Alison ^a   Walsh, Zoe Ann ^a  

^a PRINCESS ALEXANDRA HOSPITAL   (Australia)

^b ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

Author keywords

Azothioprine; Cyclosporine; Dyslipidaemia; Renal allograft; Simvastatin

Indexed keywords

ANTILIPEMIC AGENT; APOLIPOPROTEIN B; AZATHIOPRINE; CHOLESTEROL; CREATININE; CYCLOSPORIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN;

ABDOMINAL PAIN; ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DYSLIPIDEMIA; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; KIDNEY ALLOGRAFT; MAJOR CLINICAL STUDY; MALE; MUSCULOSKELETAL DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT;

ADOLESCENT; ADULT; AGED; ANTILIPEMIC AGENTS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPERLIPIDEMIAS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SIMVASTATIN;

EID: 0033406881     PISSN: 09020063     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-0012.1999.130613.x     Document Type: Article

References (20)

1. BRUNNER FP, FASSBINDER W, OULES R, BROYER M, BRYNGER H, RIZZONI G, CHALLAH S, SELWOOD NH, DYKES SR, WING AJ. Survival on renal replacement therapy; data from the EDTA registry. Nephrol Dial Transplant 1988: 3 (2): 109-122.
2. GHOSH P, EVANS DB, TOMLINSON SA, CAINE RY. Plasma lipids following renal transplantation. Tranplantation 1973: 15: 521-523.
3. VATHSALA A, WEINBERG L, SCHOENBERG Y, GREVEL J, DUNN J, GOLDSTEIN RA, VAN BUREN CT, LEWIS RM, KAHAN BD. Lipid abnormalities in renal transplant recipients treated with cyclosporin. Transplant Proced 1989: 21: 3670-3673.
4. ISONIEMI H. Hyperlipidaemia after renal transplantation - facts and potential implications. Nephrol Dial Transplant 1995: 10 (4): 457-459.
5. WEBB AT, REAVELY DA, O'DONNELL M, O'CONNOR B, SEED M, BROWN EA. Does cyclosporin increase lipo-protein(a) concentrations in renal transplant recipients? Lancet 1993: 34: 268-270.
6. APPEL G. Lipid abnormalities in renal disease. Kidney Int 1991: 39: 169-183.
7. TONSTAD S, HOLDAAS H, GORBITZ C, OSE L. Is dietary intervention effective in post transplant hyperlipidaemia? Nephrol Dial Transplant 1995: 10 (1): 82-85.
8. FRIEDEWALD WT, LEVY RI, FREDRICKSON DS. Estimation of the concentration of low density lipoprotein cholesterol in plasma without the use of preparative ultracentrifuge. Clin Chem 1972: 18: 499-502.
9. BROOKS CA, CRAMER SM, ROSANO TG. Preparative chromatographic purification of cyclosporine metabolites. Clin Chem 1993: 39 (3): 457-466.
10. SHEPHERD J, COBBE SM, FORD I, ISLES CG, LORIMER AR. MACFARLANE PW, MCKILLOP JH, PACKARD CJ. The West of Scotland Prevention Study Group: prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995: 333 (20): 1301-1307.
11. SCANDINAVIAN SIMVASTATIN SURVIVAL STUDY GROUP: Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994: 344: 1383-1389.
12. CORPIER CL, JONES PH, SUKI WN, LEDERER ED, QUINONES MA, SCHMIDT SW, YOUNG JB. Rhabdomyolysis and renal injury with lovostatin use. JAMA 1988: 260 (2): 239-241.
13. MARAIS GE, LARSON KK. Rhabdomyolysis and acute renal failure induced by combination lovostatin and gemfibrozil therapy. Ann Intern Med 1990: 112 (3): 229-230.
14. EAST C, ALIVIZATOS PA, GRUNDY SM, FARMER JA, JONES PH. Rhabdomyolysis in patients receiving lovostatin after cardiac transplantation. New Engl J Med 1988: 318: 47-48.
15. ARNADOTTIR M, ERICKSON L-O, THYSELL H, KARKAS JD. Plasma concentration of simvastatin 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitary activity in kidney transplant recipients with and without cyclosporin. Nephrology 1993: 65 (3): 410-413.
16. KASISKE BL, TORTORICE KL, HEIM-DUTHOY KL, GORYANCE JM, RAO KV. Lovostatin treatment of hypercholesterolemia in renal transplant recipients. Transplantation 1990: 49 (1): 95-100.
17. KUO PC, KIRSHENBAUM JM, GORDON J, LAFFEL G, YOUNG P, DISESA VJ, MUDGE JH JR, VAUGHAN DE. Lovostatin therapy for hypercholesterolemia in cardiac transplant recipients. Am J Cardiol 1989: 64 (10): 631-635.
18. YOSHIMURA N, OKA T, OKAMOTO M, OHMORI Y. The effects of pravastatin on hyperlipidemia in renal transplant recipients. Transplantation 1992: 53 (1): 94-99.
19. GOLDBERG RB, ROTH D. A preliminary report of the safety and efficacy of fluvastatin for hypercholesterolemia in renal transplant patients receiving cyclosporine. Am J Cardiol 1995: 76: 107A-109A.
20. MARTINEZ HERNANDEZ BE, PERSAUD JW, VARGHESE Z, MOORHEAD JF. Low-dose simvastatin is safe in hyperlipidaemic renal transplant patients. Nephrol Dial Transplant 1993: 8 (7): 637-641.